Comparative Pharmacology
Head-to-head clinical analysis: DDAVP NEEDS NO REFRIGERATION versus STIMATE.
Head-to-head clinical analysis: DDAVP NEEDS NO REFRIGERATION versus STIMATE.
DDAVP (NEEDS NO REFRIGERATION) vs STIMATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption and concentrate urine. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor activation on endothelial cells.
Desmopressin acetate is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). It acts as a V2 receptor agonist in the renal collecting ducts, increasing water permeability and promoting water reabsorption, thereby reducing urine output. It also increases plasma levels of von Willebrand factor and factor VIII via V2 receptor stimulation on endothelial cells.
1-2 mg orally twice daily for central diabetes insipidus; intranasal 10-40 mcg/day in 1-3 divided doses; IV/SC 0.5-2 mcg/day in divided doses for diabetes insipidus.
Intranasal: 1 spray (1.5 mg) into one nostril, 1 hour prior to voiding or on awakening for bedwetting; maximum 2 sprays per day.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours for intravenous and oral routes; increased to 3-5 hours in patients with renal impairment.
Terminal elimination half-life is approximately 3-4 hours in healthy adults, but may be prolonged in patients with renal impairment or in older adults.
Primarily renal (approximately 60-70% excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Desmopressin is primarily excreted renally, with approximately 60-70% of the dose recovered unchanged in urine within 24 hours. The remaining fraction is metabolized hepatically and eliminated via feces.
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog